SG11201803913RA - Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain - Google Patents

Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain

Info

Publication number
SG11201803913RA
SG11201803913RA SG11201803913RA SG11201803913RA SG11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA
Authority
SG
Singapore
Prior art keywords
international
opioid
oxide derivative
pct
cambridgeshire
Prior art date
Application number
SG11201803913RA
Other languages
English (en)
Inventor
Steve Whitelock
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of SG11201803913RA publication Critical patent/SG11201803913RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201803913RA 2015-11-19 2016-11-18 Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain SG11201803913RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1520390.4A GB201520390D0 (en) 2015-11-19 2015-11-19 Composition
PCT/GB2016/053600 WO2017085502A1 (en) 2015-11-19 2016-11-18 Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain

Publications (1)

Publication Number Publication Date
SG11201803913RA true SG11201803913RA (en) 2018-06-28

Family

ID=55133015

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803913RA SG11201803913RA (en) 2015-11-19 2016-11-18 Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain

Country Status (14)

Country Link
US (1) US20180344726A1 (cg-RX-API-DMAC7.html)
EP (1) EP3377048B1 (cg-RX-API-DMAC7.html)
JP (1) JP2018534319A (cg-RX-API-DMAC7.html)
KR (1) KR20180074797A (cg-RX-API-DMAC7.html)
CN (1) CN108601747A (cg-RX-API-DMAC7.html)
AU (1) AU2016355113A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018009886A2 (cg-RX-API-DMAC7.html)
CA (1) CA3005775A1 (cg-RX-API-DMAC7.html)
ES (1) ES2799516T3 (cg-RX-API-DMAC7.html)
GB (1) GB201520390D0 (cg-RX-API-DMAC7.html)
IL (1) IL259457A (cg-RX-API-DMAC7.html)
MX (1) MX2018006157A (cg-RX-API-DMAC7.html)
SG (1) SG11201803913RA (cg-RX-API-DMAC7.html)
WO (1) WO2017085502A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210078515A (ko) * 2018-10-18 2021-06-28 아비어, 인크. 만성 신장 질환-연관 소양증의 치료 방법 및 장치

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722928A (en) * 1985-12-02 1988-02-02 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
SI2283842T1 (sl) * 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
GB0026137D0 (en) * 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
JP4949625B2 (ja) * 2002-06-10 2012-06-13 ユーロ−セルティーク エス.エイ. 経皮送達デバイスに含有された活性薬剤の誤用を防止する、経皮送達デバイスの廃棄システム
EP1718258B1 (en) * 2004-02-23 2009-03-25 Euro-Celtique S.A. Abuse resistance opioid transdermal delivery device
US20080234306A1 (en) * 2006-11-22 2008-09-25 Progenics Pharmaceuticals, Inc. N-Oxides of 4,5-Epoxy-Morphinanium Analogs
WO2009067275A1 (en) * 2007-11-21 2009-05-28 Progenics Pharmaceuticals, Inc N-oxides of 4,5-epoxy-morphinanium analogs
CA2718943A1 (en) * 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
US8829020B2 (en) * 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
EP3064199B1 (en) * 2010-04-02 2023-12-20 Buzzz Pharmaceuticals Limited Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists

Also Published As

Publication number Publication date
US20180344726A1 (en) 2018-12-06
MX2018006157A (es) 2019-04-04
ES2799516T3 (es) 2020-12-18
EP3377048B1 (en) 2020-04-22
GB201520390D0 (en) 2016-01-06
CN108601747A (zh) 2018-09-28
EP3377048A1 (en) 2018-09-26
WO2017085502A1 (en) 2017-05-26
BR112018009886A2 (pt) 2018-11-13
IL259457A (en) 2018-07-31
CA3005775A1 (en) 2017-05-26
KR20180074797A (ko) 2018-07-03
JP2018534319A (ja) 2018-11-22
AU2016355113A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201806745RA (en) Sulfonylureas and related compounds and use of same
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201804312RA (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
SG11201804934PA (en) Novel Compounds
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201803686UA (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201806485RA (en) Pyrrolobenzodiazepine conjugates
SG11201408279QA (en) Social sharing of security information in a group
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201806623VA (en) Bacteria over-expressing c-di-amp and therapeutic methods
SG11201807549TA (en) Combination of a cxcr4 antagonist and an immune checkpoint inhibitor
SG11201408509PA (en) Racecadotril lipid compositions
SG11201806424TA (en) Therapeutic compounds
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones